12:00 AM
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Prevnar 13 regulatory update

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommended the use of Pfizer's Prevnar 13 for adults >=19 years with immunocompromising conditions, including those with functional or anatomic asplenia, HIV infection, cancer or advanced kidney disease. Pfizer said there are no data on the safety or...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >